'N of 1' therapies addressed in draft FDA guidance
Recognizing the pace at which drug developers are moving ever further into individualized medicine, the FDA has issued a draft guidance addressing submission processes for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.